| ā | Case | Age | Sex | Primary disease | Clinical manifestation | ICI therapy |
| 1 | Suozzi, 2016 [9] | 60 | F | Lung Adenocarcinoma | Cutaneous only | Ipilimumab & Nivolumab |
| 2 | Ogawa, 2018 [10] | 63 | F | Lung Adenocarcinoma | Cutaneous only | Nivolumab |
| 3 | Birnbaum, 2017 [11] | 56 | F | Melanoma | Cutaneous only | Nivolumab |
| 4 | Dimitriou, 2018 [12] | 72 | M | Melanoma | Cutaneous only | Pembrolizumab |
| 5 | Tetzlaff, 2017 [2] | 57 | F | Ovarian Cancer | Subcutaneous only (bilateral lower extremities, forearms) | Ipilimumab & Nivolumab |
| 6 | Tetzlaff, 2017 [2] | 39 | F | Melanoma | Subcutaneous only (bilateral lower extremities & buttocks) | Ipilimumab & Nivolumab |
| 7 | Current Report, 2019 | 49 | F | Renal Cell Carcinoma | Cutaneous only (left forearm and elbow) | Ipilimumab & Nivolumab |
| 8 | Current Report, 2019 | 58 | M | Melanoma | Cutaneous only (black tattoo on chest, shoulders, back, forearm, thigh) | Ipilimumab |
| 9 | Kim, 2016 [14] | 52 | M | Urothelial Carcinoma | Cutaneous (tattoo & face), Hilar Lymph Nodes (LN) | Ipilimumab & Nivolumab |
| 10 | Cotliar, 2016 [16] | 72 | F | Hodgkin Lymphoma | Subcutaneous (bilateral arms), Pulmonary, Hilar LN, Bone | Pembrolizumab |
| 11 | Tetzlaff, 2018 [13] | 44 | F | Melanoma | Subcutaneous (peripatellar), Hilar LN | Ipilimumab |
| 12 | Tetzlaff, 2018 [13] | 79 | M | Melanoma | Cutaneous (bilateral forearms, elbows, hands), Hilar LN | Pembrolizumab & Nivolumab |
| 13 | Le Burel, 2017 [17] | 71 | F | Melanoma | Cutaneous, Pulmonary Parenchyma | Nivolumab |
| 14 | Lomax, 2017 [18] | 75 | F | Melanoma | Cutaneous, Pulmonary | Nivolumab |
| 15 | Oommen, 2017 [19] | 54 | M | Melanoma | Cutaneous, Pulmonary | Ipilimumab |
| 16 | Reddy, 2017 [20] | 57 | F | Melanoma | Cutaneous, Pulmonary | Ipilimumab |
| 17 | Reddy, 2017 [20] | 55 | F | Melanoma | Cutaneous, Pulmonary | Ipilimumab & Nivolumab |
| 18 | Toumeh, 2016 [21] | 26 | F | Melanoma | Cutaneous, Pulmonary | Ipilimumab |
| 19 | Yatim, 2018 [22] | 72 | F | Melanoma | Subcutaneous (left flank, right leg, scar), Pulmonary, hilar LN, Eye | Pembrolizumab |
| 20 | Firwana, 2017 [23] | 37 | F | Melanoma | Cutaneous (right forearm, bilateral shins), Hilar LN & other LN | Ipilimumab & Pembrolizumab |
| 21 | Firwana, 2017 [23] | 57 | F | Melanoma | Cutaneous (bilateral lower extremities), Hilar LN | Ipilimumab |
| 22 | Danlos, 2016 [24] | 57 | M | Melanoma | Cutaneous (lip, scar), Hilar and Mediastinal LN | Nivolumab |
| 23 | Martinez, 2016 [25] | 46 | F | Melanoma | Cutaneous, Pulmonary | Ipilimumab |
| 24 | Tissot, 2013 [26] | 57 | M | Melanoma | Cutaneous (elbow, arm), Pulmonary, Hilar LN | Ipilimumab |
| 25 | Eckert, 2009 [8] | 67 | F | Melanoma | Cutaneous, Pulmonary | Ipilimumab |
| 26 | Reule, 2013 [27] | 55 | M | Melanoma | Cutaneous (finger, forearm, knee), Pulmonary, Hilar LN | Ipilimumab |
| 27 | Lomax, 2017 [18] | 57 | F | Melanoma | Subcutaneous & Cutaneous (elbows, wrists, thighs), Pulmonary, Hilar LN | Pembrolizumab |
| 28 | McKenna, 2018 [28] | 69 | F | Melanoma | Cutaneous, Pulmonary | Nivolumab |
| 29 | Jespersen, 2018 [29] | 57 | F | Melanoma | Cutaneous, Pulmonary, Bone | Pembrolizumab |
| 30 | Dimitriou, 2018 [12] | 65 | M | Melanoma | Cutaneous (elbow), Hilar LN | Pembrolizumab |
| 31 | Dimitriou, 2018 [12] | 57 | M | Melanoma | Cutaneous (scar), Hilar LN, Thyroid | Ipilimumab & Nivolumab |
| 32 | Burillo-Martinez, 2017 [30] | 69 | F | Melanoma | Subcutaneous (forearms, legs, blue nevus), Hilar LN | Pembrolizumab |
| 33 | Paolini, 2018 [31] | 56 | F | Non-small Cell Lung Cancer | Cutaneous, Pulmonary | Nivolumab |
| 34 | Wilgenhof, 2012 [32] | 37 | M | Melanoma | Cutaneous, Pulmonary, Lymph Nodes, Spleen | Ipilimumab |
| 35 | Lomax, 2017 [18] | 44 | M | Melanoma | Cutaneous (elbow and occipital region), Pulmonary, Hilar and Mediastinal LN, Colitis | Nivolumab |
| 36 | Lomax, 2017 [18] | 65 | F | Melanoma | Cutaneous (face, knees), Thyroiditis, Pulmonary, Hilar LN | Pembrolizumab |
|
|